A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others.

By the time Don Jr. made his return visit that December for the trip Ches McDowell proposed, he’d gone from son of a mogul to member of the First Family-elect. McDowell arranged for one of North ...

Our KRIS 6 Hooks Kid Reporter Lilly sat down with new catcher Garret Guillemette. The Hooks are on a 3-game road trip to San ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Eli Lilly and Company (NYSE:LLY) is one of the 17 stocks that Jim Cramer commented on. ... They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Image source: Getty Images. A big catalyst could be coming soon.

Camurus may earn up to $870 million in milestone payments and royalties from the deal. Lilly to develop and commercialize up to four incretin drug compounds globally. Get ahead of Wall Street ...

A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.